NCT00304460 2019-12-12
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
5 trialsNCT00923390 2019-04-09
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00418496 2017-02-20
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT00006022 2015-12-14
Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
Virginia Commonwealth University
Phase 1 Completed
NCT00004890 2013-03-26
Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer
National Cancer Institute (NCI)
Phase 1 Completed